Cadrenal Therapeutics insider files to sell 1,700 shares; recent 10b5-1 sales totaled 14,500 shares

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) notice reports a proposed sale of 1,700 common shares, with an aggregate market value of $23,511, representing part of 2,046,854 shares outstanding. The sale is scheduled approximately for 10/01/2025 and the broker listed is Morgan Stanley Smith Barney LLC.

The shares to be sold were acquired as Founders Shares on 05/17/2022. Over the past three months the filer completed 5 sales totaling 14,500 shares for aggregate gross proceeds of $203,567.01 under 10b5-1 plans on dates between 08/27/2025 and 09/29/2025. The filer certifies no undisclosed material adverse information.

Positive

• Filer used a broker (Morgan Stanley Smith Barney LLC), indicating organized execution of the planned sale
• Sales occurred under 10b5-1 plans, which provides structured, pre-arranged trading and reduces insider trading concerns
• Filer certified no undisclosed material adverse information as required on the form

Negative

• Insider selling of 14,500 shares in the past three months (14,500 of 2,046,854 outstanding) represents ongoing dilution of insider holdings
• Filing does not disclose the filer’s percentage ownership, limiting assessment of the sale’s significance to insider stake

Insights

Securities Analyst

TL;DR Transaction volume is modest versus outstanding shares and reflects routine insider liquidity under a 10b5-1 plan.

The proposed sale of 1,700 shares equals 0.083% of the 2,046,854 shares outstanding, indicating limited dilution or market impact. Recent 10b5-1 sales of 14,500 shares generated $203,567.01, showing ongoing structured dispositions rather than opportunistic block liquidation. No financial results or material corporate events are disclosed in this filing, so the filing itself is a routine disclosure of insider selling.

Corporate Governance Expert

TL;DR Filing documents compliance with Rule 144 and 10b5-1 procedures and includes the required seller certifications.

The form indicates the securities were acquired as founders shares and that the filer affirms absence of undisclosed material information. Use of a named broker (Morgan Stanley Smith Barney LLC) and prior 10b5-1 sales suggests governance controls around insider trading. The filing contains standard representations and no governance red flags are evident from the disclosed items alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1700	23511.00	2046854	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2022	Founders Shares	Issuer			1700	05/17/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/29/2025	100	1400.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/25/2025	10900	153182.06
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/24/2025	1500	20992.95
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/28/2025	400	5600.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/27/2025	1600	22392.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being proposed for sale in the CVKD Form 144?

The filer proposes to sell 1,700 common shares of Cadrenal Therapeutics with an aggregate market value of $23,511, approximately on 10/01/2025.

How many shares has the insider sold recently according to the filing?

The filing lists five 10b5-1 sales totaling 14,500 shares completed between 08/27/2025 and 09/29/2025 for gross proceeds of $203,567.01.

When were the shares to be sold originally acquired?

The shares were acquired as Founders Shares on 05/17/2022.

Which broker is handling the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filing indicate any undisclosed material information?

By signing the Form 144, the filer represents they do not know any material adverse information regarding the issuer that has not been publicly disclosed.